

HALOZYME THERAPEUTICS INC

Form 4

July 02, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lim Jonathan E

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, SUITE 17

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
HALOZYME THERAPEUTICS INC [HALO]

3. Date of Earliest Transaction (Month/Day/Year)  
06/29/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President, CEO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2007		M <sup>(1)</sup>		25,000	A	\$ 0.39
Common Stock	06/29/2007		S <sup>(1)</sup>		100	D	\$ 9.16
Common Stock	06/29/2007		S <sup>(1)</sup>		100	D	\$ 9.17
Common Stock	06/29/2007		S <sup>(1)</sup>		100	D	\$ 9.18

## Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	200	D	\$ 9.23	697,810	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	100	D	\$ 9.24	697,710	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 9.26	697,410	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	200	D	\$ 9.27	697,210	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	100	D	\$ 9.28	697,110	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	800	D	\$ 9.3	696,310	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	600	D	\$ 9.32	695,710	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	900	D	\$ 9.33	694,810	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	1,100	D	\$ 9.36	693,710	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	600	D	\$ 9.37	693,110	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	600	D	\$ 9.38	692,510	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	300	D	\$ 9.385	692,210	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	1,960	D	\$ 9.39	690,250	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	286	D	\$ 9.4	689,964	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	681	D	\$ 9.41	689,283	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	400	D	\$ 9.48	688,883	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	100	D	\$ 9.49	688,783	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	1,100	D	\$ 9.5	687,683	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	100	D	\$ 9.505	687,583	D
Common Stock	06/29/2007	<u>S<sup>(1)</sup></u>	2,000	D	\$ 9.51	685,583	D
	06/29/2007	<u>S<sup>(1)</sup></u>	100	D		685,483	D

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock						\$ 9.515	
Common Stock	06/29/2007	S <sup>(1)</sup>	1,374	D	\$ 9.52	684,109	D
Common Stock	06/29/2007	S <sup>(1)</sup>	500	D	\$ 9.53	683,609	D
Common Stock	06/29/2007	S <sup>(1)</sup>	200	D	\$ 9.535	683,409	D
Common Stock	06/29/2007	S <sup>(1)</sup>	700	D	\$ 9.54	682,709	D
Common Stock	06/29/2007	S <sup>(1)</sup>	1,200	D	\$ 9.55	681,509	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	\$ 0.39	06/29/2007		M <sup>(1)</sup>	25,000	11/11/2003	11/11/2013	Common Stock	25,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lim Jonathan E C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY ROAD, SUITE 17	X		President, CEO	

SAN DIEGO, CA 92121

## Signatures

/s/ Jonathan E.

06/29/2007

Lim

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.